Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants
Authors:
Open Access
- 24 March 2022
- journal article
- research article
- Published by Elsevier in Antiviral Research
- Vol. 201, 105297
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B CellsCell, 2020
- Identification of Human Single-Domain Antibodies against SARS-CoV-2Cell Host & Microbe, 2020
- Human neutralizing antibodies elicited by SARS-CoV-2 infectionNature, 2020
- A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2Nature, 2020
- Coronavirus disease 2019 (COVID-19): research progress and clinical practiceGlobal Health & Medicine, 2020
- In Vivo CD4+T Cell Differentiation and Function: Revisiting the Th1/Th2 ParadigmAnnual Review of Immunology, 2020
- Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infectionJournal of Experimental Medicine, 2011
- Screening individual hybridomas by microengraving to discover monoclonal antibodiesNature Protocols, 2009
- Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individualsNature, 2009
- An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirusNature Medicine, 2004